Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1026-1031

  Koh, Y ^a   Lim, H Y ^b   Ahn, J H ^c   Lee, J L ^c   Rha, S Y ^d   Kim, Y J ^e   Kim, T M ^a   Lee, S H ^a  

^a Seoul National University Hospital   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

Author keywords

Everolimus; Nonclear cell; RAD001; Renal cell carcinoma

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CHROMOPHOBE ADENOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY CARCINOMA; KOREA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NONCLEAR-CELL RENAL CELL CARCINOMA; PAPILLARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; TREATMENT RESPONSE;

EID: 84875614863     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds582     Document Type: Article

References (25)

1. Siegel R, Ward E, Brawley O et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Lopez-Beltran A, Scarpelli M, Montironi R et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
3. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.
4. Tazi El M, Essadi I, Tazi MF et al. Advanced treatments in non-clear renal cell carcinoma. Urol J 2011; 8: 1-11.
5. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
6. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007; 356: 125-134.
7. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
8. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119-1132.
9. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
10. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
11. Christian UB, Petri B, James MGL et al. Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT. J Clin Oncol 2012; 30: abstr 402.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
13. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23: 2763-2771.
14. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
15. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799.
16. Chowdhury S, Matrana MR, Tsang C et al. Systemic therapy for metastatic nonclear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am 2011; 25: 853-869.
17. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 2376-2381.
18. Albiges L, Molinie V, Escudier B. Non-clear cell renal cell carcinoma: does the Mammalian target of rapamycin represent a rational therapeutic target. Oncologist 2012; 17: 1051-1062.
19. Nickerson ML, Warren MB, Toro JR et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002; 2: 157-164.
20. Hasumi Y, Baba M, Ajima R et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci USA 2009; 106: 18722-18727.
21. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
22. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841.
23. Lee JL, Ahn JH, Lim HY et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012; 23: 2108-2114.
24. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
25. Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26: 202-209.